(Q35689833)

English

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

scientific article published on 13 March 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Somnuek Sungkanuparph

4

object named as

Somnuek Sungkanuparph

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Weerawat Manosuthi

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sukanya Chimsuntorn

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sirirat Likanonsakul

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

13 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

AIDS Research and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

27 July 2018

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

27 July 2018

Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

27 July 2018

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

27 July 2018

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Hepatotoxicity associated with nevirapine use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

High hepatotoxicity rate seen among HAART patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828738

25 September 2018

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/17352834

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1742-6405-4-6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35689833&oldid=2197628360"